OTCMSZLSF
Market cap120kUSD
Dec 23, Last price
0.00USD
1D
-94.32%
1Q
-98.28%
Name
StageZero Life Sciences Ltd
Chart & Performance
Profile
StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in the United States and Canada. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is Aristotle, a multi-cancer panel test for simultaneously screening for various cancers from a single sample of blood with high sensitivity and specificity for each cancer. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; COVID polymerase chain reaction testing and blood test analysis; Prostate Health Index, a screening test for prostate cancer; and BreastSentry, a test to determine a woman's risk for developing breast cancer. The company was founded in 1998 and is headquartered in Richmond Hill, Canada.
IPO date
Oct 30, 1998
Employees
40
Domiciled in
CA
Incorporated in
CA
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | |||||||||
Revenues | 3,795 -25.12% | 5,068 22.07% | |||||||
Cost of revenue | 11,203 | 12,888 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (7,408) | (7,819) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 3,297 | 200 | |||||||
Tax Rate | |||||||||
NOPAT | (10,705) | (8,020) | |||||||
Net income | (14,712) 91.46% | (7,684) 6.96% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,543 | 3,107 | |||||||
BB yield | -25.86% | -14.65% | |||||||
Debt | |||||||||
Debt current | 1,224 | 580 | |||||||
Long-term debt | 770 | 1,192 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 601 | 2,363 | |||||||
Net debt | 1,978 | 47 | |||||||
Cash flow | |||||||||
Cash from operating activities | (3,529) | (8,955) | |||||||
CAPEX | (148) | ||||||||
Cash from investing activities | (21) | ||||||||
Cash from financing activities | 1,833 | 4,103 | |||||||
FCF | (6,511) | (5,852) | |||||||
Balance | |||||||||
Cash | 16 | 1,725 | |||||||
Long term investments | |||||||||
Excess cash | 1,471 | ||||||||
Stockholders' equity | (20,412) | (9,798) | |||||||
Invested Capital | 15,311 | 16,279 | |||||||
ROIC | |||||||||
ROCE | 145.20% | ||||||||
EV | |||||||||
Common stock shares outstanding | 99,426 | 70,716 | |||||||
Price | 0.06 -80.00% | 0.30 -60.00% | |||||||
Market cap | 5,966 -71.88% | 21,215 -36.89% | |||||||
EV | 7,944 | 21,262 | |||||||
EBITDA | (6,970) | (7,310) | |||||||
EV/EBITDA | |||||||||
Interest | 219 | 200 | |||||||
Interest/NOPBT |